Neogenomics Inc (NEO) Financial Statements
Industry: Testing Laboratories (Services)
In fiscal 2025, Neogenomics reported revenue of $727.3M, up 10.1% from $660.6M the year before. Net income was -$108.0M (a -14.9% net margin), or -$0.84 per diluted share. Gross margin was 43.2% and operating margin was -15.9%. Operating activities generated $5.2M of cash, leaving -$21.8M of free cash flow. At fiscal year end, Neogenomics held $1.36B in total assets against $523.3M in total liabilities, including $159.6M of cash and equivalents.
Open the full interactive Neogenomics financials → Quarterly statements, key ratios, valuation history and price charts.
Neogenomics Key Stats
| Share Price | $16.66 |
|---|---|
| Market Cap | $2.18B |
| Revenue YoY Growth | +10.1% |
| 52-Week Range | $7.19 – $19.91 |
| Shares Outstanding | 129.6 million (basic, 2026 Q2) |
Neogenomics Income Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Revenue | $444.4M | $484.3M | $509.7M | $591.6M | $660.6M | $727.3M |
| Cost of Goods Sold | $258.6M | $297.3M | $321.8M | $347.0M | $370.5M | $413.0M |
| Gross Profit | $185.9M | $187.1M | $187.9M | $244.6M | $290.1M | $314.3M |
| Operating Income | -$14.0M | -$118.8M | -$157.6M | -$107.7M | -$92.1M | -$115.9M |
| Pre-Tax Income | -$14.1M | -$15.1M | -$159.3M | -$97.1M | -$80.7M | -$110.3M |
| Income Tax | -$18.2M | -$6.7M | -$15.1M | -$9.1M | -$1.9M | -$2.2M |
| Net Income | $4.2M | -$8.3M | -$144.2M | -$88.0M | -$78.7M | -$108.0M |
| Diluted EPS | $0.04 | -$0.07 | -$1.16 | -$0.70 | -$0.62 | -$0.84 |
Neogenomics Quarterly Results
| 2025 Q3 | 2025 Q4 | 2026 Q1 | 2026 Q2 | |
|---|---|---|---|---|
| Revenue | $187.8M | $190.2M | $186.7M | $201.7M |
| Net Income | -$27.1M | -$9.9M | -$17.1M | $2.2M |
| Diluted EPS | -$0.21 | -$0.08 | -$0.13 | $0.02 |
Neogenomics Balance Sheet
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $228.7M | $316.8M | $263.2M | $342.5M | $367.0M | $159.6M |
| Current Assets | $448.7M | $681.5M | $605.3M | $596.8M | $596.0M | $376.3M |
| Total Assets | $988.3M | $1.87B | $1.74B | $1.68B | $1.64B | $1.36B |
| Current Liabilities | $73.2M | $87.2M | $89.9M | $96.3M | $301.2M | $88.3M |
| Total Long-Term Debt | $171.9M | $533.7M | $535.4M | $538.2M | $541.1M | $341.9M |
| Total Liabilities | $294.0M | $761.5M | $742.0M | $739.7M | $735.7M | $523.3M |
| Shareholders' Equity | $694.3M | $1.11B | $998.0M | $941.5M | $902.3M | $836.6M |
Neogenomics Cash Flow Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash From Operations | $1.5M | -$26.7M | -$66.0M | -$2.0M | $7.0M | $5.2M |
| Cash From Investing | -$159.4M | -$632.4M | $517,000 | $76.7M | $12.9M | -$12.3M |
| Cash From Financing | $235.6M | $725.3M | $11.8M | $4.6M | $4.6M | -$200.3M |
| Free Cash Flow | -$27.6M | -$90.9M | -$96.9M | -$30.7M | -$34.0M | -$21.8M |
Figures from Neogenomics' 10-K and 10-Q filings with the SEC, as of 2026-10-14. Fiscal years follow the company's own reporting calendar. EPS and share counts are adjusted for later stock splits. See the full Neogenomics financials page for every line item.
Neogenomics Company Profile
| Ticker | NEO |
|---|---|
| Exchange | Nasdaq |
| Industry | Testing Laboratories (Services) |
| Headquarters | Fort Myers, Florida |
| Incorporated in | Nevada |
| Fiscal Year End | December 31 |
| SEC Filer Category | Large accelerated filer |
| SEC CIK | 0001077183 |
Frequently Asked Questions
What was Neogenomics' revenue in fiscal 2025?
Neogenomics (NEO) reported revenue of $727.3M for fiscal 2025.
What is Neogenomics' annual revenue history?
Neogenomics' annual revenue by fiscal year: 2020: $444.4M; 2021: $484.3M; 2022: $509.7M; 2023: $591.6M; 2024: $660.6M; 2025: $727.3M.
What was Neogenomics' net income in fiscal 2025?
Neogenomics reported net income of -$108.0M for fiscal 2025.
What was Neogenomics' earnings per share (EPS) in fiscal 2025?
Neogenomics' diluted EPS was -$0.84 for fiscal 2025 (adjusted for any later stock splits).
How much free cash flow did Neogenomics generate in fiscal 2025?
Neogenomics generated -$21.8M of free cash flow in fiscal 2025.
What was Neogenomics' revenue last quarter?
In its most recent reported quarter (2026 Q2), Neogenomics reported revenue of $201.7M.
How much debt does Neogenomics have?
Neogenomics reported $341.9M of long-term debt, including the current portion, at the end of fiscal 2025.
How many shares of Neogenomics are outstanding?
Neogenomics reported a weighted average of 129.6 million basic shares outstanding in 2026 Q2.
What is Neogenomics' market cap?
Based on its latest closing price, Neogenomics (NEO) has a market capitalization of about $2.18B.
When does Neogenomics' fiscal year end?
Neogenomics' fiscal year end, as registered with the SEC, is December 31.
Where is Neogenomics headquartered?
Neogenomics lists its business address in Fort Myers, Florida in its SEC filings.